Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer

Documenti analoghi

• Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR‐mutated lung cancer and pulmonary tuberculosis: A case report
  di: Hiroaki Matsuura, et al.
  Pubblicazione: (2024)
• Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy
  di: David R. Gandara, et al.
  Pubblicazione: (2026)
• Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer
  di: Ayako Morita, et al.
  Pubblicazione: (2024)
• Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
  di: Hayato Koba, et al.
  Pubblicazione: (2024)
• Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion–insertion R) in an advanced non‐small cell lung cancer patient
  di: Akiko Tamura, et al.
  Pubblicazione: (2024)